Clinical Trials Market Size To Reach $158.41 Billion By 2033

October 2025 | Report Format: Electronic (PDF)

Clinical Trials Market Growth & Trends

The global clinical trials market size is estimated to reach USD 158.41 billion by 2033, registering a CAGR of 7.48% from 2025 to 2033, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug.

The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.

The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.

key Request a free sample copy or view report summary: Clinical Trials Market Report

Clinical Trials Market Report Highlights

Based on phase, the phase III clinical trials segment dominated the market with a 53.48% share in 2024. This can be attributed to the complexity of this phase.
Based on study design, the interventional studies segment dominated the market in 2024. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers.
Based on indication, oncology segment accounted for largest market revenue share in 2024.
Based on indication by study design, the autoimmune/inflammation segment accounted for largest market revenue share in 2024. This can be attributed to large number of interventional studies on autoimmune/inflammation worldwide.
Based on service, the patient recruitment and retention segment garnered significant market share in 2024, key reasons supporting the demand is the growing number of clinical studies globally.
Based on sponsor, the pharmaceutical & biopharmaceutical companies accounted for largest market revenue share in 2024.
North America held 50.9% of the market share in 2024. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth
Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period, owing to the increasing patient pool and cost-efficient services.

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, indication by study design, service, sponsor, and region:

Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I
Phase II
Phase III
Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional Trials
Observational Trials
Expanded Access Trials

Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome (IBS)
- Others
Pain Management
- Chronic Pain
- Acute Pain
Oncology
- Blood Cancer
- Solid Tumors
- Others
CNS Conditions
- Epilepsy
- Parkinson's Disease (PD)
- Huntington's Disease
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle Regeneration
- Others
Diabetes
Obesity
Cardiovascular Diseases
Others

Clinical Trials Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Pain Management
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Oncology
- Interventional Trials
- Observational Trials
- Expanded Access Trials
CNS Conditions
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Diabetes
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Obesity
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Cardiovascular Diseases
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Others
- Interventional Trials
- Observational Trials
- Expanded Access Trials

Clinical Trials Service Outlook (Revenue, USD Million, 2021 - 2033)

Protocol Designing
Site Identification
Patient Recruitment
Laboratory Services
Analytical Testing Services
Clinical Trial Data Management Services
Others

Clinical Trials Sponsor Outlook (Revenue, USD Million, 2021 - 2033)

Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others

Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- India
- China
- Japan
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
- Columbia
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman